Loading...
•
Dec 31, 2024
Praxis Q4 2024 Earnings Report
Praxis Precision Medicines reported its Q4 2024 earnings, with a net loss of $58.679 million and a significant increase in cash and cash equivalents.
Key Takeaways
Praxis Precision Medicines reported a net loss of $58.679 million for Q4 2024, an increase from the $26.878 million loss in Q4 2023. Revenue from collaboration was $7.463 million. The company's cash and cash equivalents significantly increased to $469.5 million, providing a cash runway into 2028.
Net loss for Q4 2024 was $58.679 million, compared to $26.878 million in Q4 2023.
Collaboration revenue for Q4 2024 was $7.463 million, up from $515 thousand in Q4 2023.
Research and development expenses increased significantly to $56.288 million in Q4 2024 from $18.388 million in Q4 2023.
Cash, cash equivalents, and marketable securities totaled $469.5 million as of December 31, 2024, expected to fund operations into 2028.
Praxis
Praxis
Praxis Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Praxis plans to continue both Essential3 studies to completion, with topline results expected in Q3 2025. They also anticipate initiating the EMERALD study for DEEs by mid-2025 and expect topline results for RADIANT and POWER1 studies in 2025.
Positive Outlook
- Topline results for Essential3 program expected in Q3 2025.
- Initiation of EMERALD study for DEEs anticipated by mid-2025.
- Topline results for RADIANT Phase 2 study expected by mid-2025.
- Topline results for POWER1 Phase 2/3 registrational study anticipated in H2 2025.
- POWER2, the second registrational study for FOS, is on track to begin enrollment in H2 2025.
Challenges Ahead
- Interim analysis for Study 1 of Essential3 program recommended stopping for futility.
- Results of Study 1 unlikely to meet primary efficacy endpoint under current statistical model parameters.
- Underlying assumptions of the statistical model might have influenced the outcome.
- Decision on NDA submission for Essential3 will be made after analyzing final results for Study 1 and Study 2.
- No specific negative financial guidance provided, but increased R&D expenses could impact profitability.